Showing results (1-10 of 26) with videos related to
Sort By:
Pageof 3
Research and Practice in Thrombosis and Haemostasis|July 12, 2019
Asymptomatic "breakthrough" thrombosis and anticoagulant "failure": Keep calm and carry onSven R Olson, Joseph J Shatzel, Thomas G DeLougheryJournal of Thrombosis and Thrombolysis|March 29, 2020
When to consider targeted therapies in thrombotic microangiopathies in the modern era: walking the tightrope between cost, safety, and efficacyCatherine R Murphree, Sven R Olson, Thomas G DeLoughery, et al.Seminars in Thrombosis and Hemostasis|June 20, 2019
The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human TrialsEmma P DeLoughery, Sven R Olson, Cristina Puy, et al.Journal of Oncology Practice|November 11, 2017
Management of Anticoagulation in Patients With Prostate Cancer Receiving EnzalutamideJoseph J Shatzel, Molly M Daughety, Sven R Olson, et al.Computer Methods in Biomechanics and Biomedical Engineering|May 9, 2019
Modeling the effect of blood vessel bifurcation ratio on occlusive thrombus formationHari Hara Sudhan Lakshmanan, Joseph J Shatzel, Sven R Olson, et al.European Journal of Haematology|September 18, 2020
Anticoagulation strategies in extracorporeal circulatory devices in adult populationsCatherine Kato, Michael Oakes, Morris Kim, et al.American Journal of Nephrology|August 16, 2018
When to Stop Eculizumab in Complement-Mediated Thrombotic MicroangiopathiesSven R Olson, Eric Lu, Emilio Sulpizio, et al.Vox Sanguinis|February 22, 2020
Diagnosis and management of hereditary haemochromatosisCatherine R Murphree, Nga N Nguyen, Vikram Raghunathan, et al.Platelets|November 14, 2018
Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?Sven R Olson, Steven Koprowski, Justine Hum, et al.Research and Practice in Thrombosis and Haemostasis|July 12, 2019
The contact pathway and sepsisVikram Raghunathan, Jevgenia Zilberman-Rudenko, Sven R Olson, et al.Pageof 3